Adaptive Biotechnologies (ADPT) Cash from Financing Activities (2018 - 2026)

Adaptive Biotechnologies has disclosed Cash from Financing Activities across 9 years of filings, most recently posting $142.2 million for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 8731.55% year-over-year to $142.2 million; the TTM figure through Jun 2026 stood at $173.0 million (up 2293.88% YoY), while the FY2025 annual figure was $30.4 million, up 12515.35% from the prior year.
• Cash from Financing Activities came in at $142.2 million for Q2 2026 at Adaptive Biotechnologies, up from $7.5 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $142.2 million in Q2 2026 to a low of $6000.0 in Q4 2022.
• Average Cash from Financing Activities over 5 years is $17.5 million, with a median of $1.5 million recorded in 2023.
• Year-over-year, Cash from Financing Activities tumbled 99.99% in 2023 and surged 16953.54% in 2025.
• Over 5 years, Cash from Financing Activities stood at $6000.0 in 2022, then surged by 1350.0% to $87000.0 in 2023, then soared by 45.98% to $127000.0 in 2024, then surged by 16953.54% to $21.7 million in 2025, then jumped by 556.51% to $142.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $142.2 million in Q2 2026, $7.5 million in Q1 2026, and $21.7 million in Q4 2025.